Ingalls & Snyder LLC’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ingalls & Snyder LLC’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,760	Closed	-$314K	–	456
2022 Q4	$314K	Buy	+2,760	New	+$229K	0.02%	338
2022 Q3	–	Sell	-2,864	Closed	-$228K	–	460
2022 Q2	$228K	Hold	2,864	–	–	0.01%	388
2022 Q1	$301K	Buy	2,864 +19	+0.7%	+$1.85K	0.01%	373
2021 Q4	$307K	Sell	2,845 -4	-0.1%	-$436	0.01%	377
2021 Q3	$312K	Sell	2,849 -140	-5%	-$14.5K	0.01%	379
2021 Q2	$280K	Sell	2,989 -71	-2%	-$6.53K	0.01%	397
2021 Q1	$282K	Buy	3,060 +158	+5%	+$13.3K	0.01%	373
2020 Q4	$212K	Buy	2,902 +175	+6%	+$13K	0.01%	398
2020 Q3	$212K	Buy	+2,727	New	+$188K	0.01%	341

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ingalls & Snyder LLC's HZNP Position: Q1 2023 in Review

Ingalls & Snyder LLC sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 2,760 shares — an estimated $314K sold.

Ingalls & Snyder LLC first reported a position in HZNP in Q3 2020 and held it in 9 quarters. The position peaked at $314K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Ingalls & Snyder LLC reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Ingalls & Snyder LLC sold 2,760 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $314K.
Ingalls & Snyder LLC first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 9 quarters.
Ingalls & Snyder LLC's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $314K in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2023, filed 9 May 2023.